Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Feb;54(2):924-6.
doi: 10.1128/AAC.00836-09. Epub 2009 Nov 23.

Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients

Denis Frasca  1 , Sandrine Marchand, Franck Petitpas, Claire Dahyot-Fizelier, William Couet, Olivier Mimoz
Affiliations
Clinical Trial

Pharmacokinetics of ertapenem following intravenous and subcutaneous infusions in patients

Denis Frasca et al. Antimicrob Agents Chemother. 2010 Feb.

Abstract

Steady-state pharmacokinetics of ertapenem were compared in patients after 1-g intravenous and subcutaneous (s.c.) infusions. Bioavailability was 99%+/-18% after s.c. administration, but peaks were reduced by about (43+/-29 versus 115+/-28 microg/ml) and times to peak were delayed. Simulations based on unbound concentrations show that time over the MIC should always be longer than 30% to 40% of the dosing interval, suggesting that s.c. infusion could be an alternative in patients with reduced vascular access.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Mean ± SD total ertapenem concentrations in plasma after multiple daily intravenous infusions (1 g over 30 min) followed by a subcutaneous infusion (1 g over 30 min) in 6 patients. Closed symbols and the solid line correspond to intravenous infusion, and open symbols and the dashed line correspond to subcutaneous infusion.
See this image and copyright information in PMC

References

    1. Barbot, A., N. Venisse, F. Rayeh, S. Bouquet, B. Debaene, and O. Mimoz. 2003. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors. Intensive Care Med. 29:1528-1534. - PubMed
    1. Boselli, E., D. Breilh, M. C. Saux, J. B. Gordien, and B. Allaouchiche. 2006. Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia. Intensive Care Med. 32:2059-2062. - PubMed
    1. Brink, A. J., G. A. Richards, V. Schillack, S. Kiem, and J. Schentag. 2008. Pharmacokinetics of once-daily dosing of ertapenem in critically ill patients with severe sepsis. Int. J. Antimicrob. Agents 33:432-436. - PubMed
    1. Burkhardt, O., M. Brunner, S. Schmidt, M. Grant, Y. Tang, and H. Derendorf. 2006. Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J. Antimicrob. Chemother. 58:632-636. - PubMed
    1. Burkhardt, O., H. Derendorf, and T. Welte. 2007. Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin. Pharmacother. 8:237-256. - PubMed

Publication types